TEVA PHARMACEUTICAL INDUSTRIES LIMITED AMERICAN DE

Teva Delivers Second Consecutive Year of Growth; Announces Strong Financial Results in Fourth Quarter and Full Year 2024, Led by Generics Performance and Innovative Portfolio Growth

29 Jan 2025 06:00:00 By Nasdaq GlobeNewswire

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab)

27 Jan 2025 05:00:00 By Nasdaq GlobeNewswire

Teva Announces Collaboration to Commercialize Formycon’s Biosimilar Candidate to Eylea® (aflibercept) in major parts of Europe and in Israel

13 Jan 2025 00:00:00 By Nasdaq GlobeNewswire

Samsung Bioepis and Teva Enter into a Strategic Partnership for Commercialization of EPYSQLI® (eculizumab-aagh) in the United States

10 Jan 2025 07:30:00 By Nasdaq GlobeNewswire

NetDania - New 12 months High: TEVA PHARMACEUTICAL INDUSTRIES LIMITED AMERICAN DE

26 Dec 2024 09:39:11 By NetDania Notify

NetDania - New 12 months High: TEVA PHARMACEUTICAL INDUSTRIES LIMITED AMERICAN DE

24 Dec 2024 08:45:03 By NetDania Notify

Teva to Present at the 43rd Annual J.P. Morgan Healthcare Conference

23 Dec 2024 15:30:00 By Nasdaq GlobeNewswire

NetDania - New 12 months High: TEVA PHARMACEUTICAL INDUSTRIES LIMITED AMERICAN DE

23 Dec 2024 15:04:36 By NetDania Notify

Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and 2025 Financial Guidance at 8 a.m. ET on January 29, 2025

20 Dec 2024 15:30:00 By Nasdaq GlobeNewswire

NetDania - New 12 months High: TEVA PHARMACEUTICAL INDUSTRIES LIMITED AMERICAN DE

20 Dec 2024 11:00:15 By NetDania Notify

NetDania - New 12 months High: TEVA PHARMACEUTICAL INDUSTRIES LIMITED AMERICAN DE

18 Dec 2024 09:01:35 By NetDania Notify

NetDania - New 12 months High: TEVA PHARMACEUTICAL INDUSTRIES LIMITED AMERICAN DE

17 Dec 2024 08:45:20 By NetDania Notify

Teva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn’s Disease

17 Dec 2024 06:30:00 By Nasdaq GlobeNewswire

Teva Announces New Patient Access Program with Direct Relief to Provide Access to Inhalers for Uninsured Patients

11 Dec 2024 07:00:00 By Nasdaq GlobeNewswire

Teva Announces Agreement to Divest Teva-Takeda, its Business Venture in Japan

05 Dec 2024 17:00:00 By Nasdaq GlobeNewswire

Teva Presents Positive Efficacy and Safety Data of AJOVY® (fremanezumab) for the Prevention of Episodic Migraine in Children and Adolescents from Phase 3 SPACE Trial

04 Dec 2024 01:00:00 By Nasdaq GlobeNewswire

Teva to Present at the 7th Annual Evercore ISI HealthCONx Conference

25 Nov 2024 17:00:00 By Nasdaq GlobeNewswire

Teva to Present at the Jefferies London Healthcare Conference

08 Nov 2024 15:30:00 By Nasdaq GlobeNewswire

NetDania - New 12 months High: TEVA PHARMACEUTICAL INDUSTRIES LIMITED AMERICAN DE

06 Nov 2024 08:46:07 By NetDania Notify

Teva Announces Strong Financial Results for the Third Quarter of 2024, led by Generics Performance and Innovative Portfolio Growth; Raises 2024 Financial Outlook including on Revenues, Adjusted EBITDA and Non-GAAP EPS

06 Nov 2024 06:00:00 By Nasdaq GlobeNewswire